Ionis Pharmaceuticals, Inc. (FRA:ISI)
Germany · Delayed Price · Currency is EUR 68.78
+1.58 (2.35%)
At close: Jan 27, 2026
Ionis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 966.96 | 705.14 | 787.65 | 587.37 | 810.46 | 729.26 | |
Revenue Growth (YoY) | 20.41% | -10.47% | 34.10% | -27.53% | 11.13% | -35.04% |
Cost of Revenue | 893.25 | 912.75 | 908.76 | 847.26 | 654.3 | 11.95 |
Gross Profit | 73.71 | -207.61 | -121.11 | -259.9 | 156.16 | 717.32 |
Selling, General & Admin | 351.76 | 267.47 | 212.62 | 150.3 | 186.35 | 354.32 |
Research & Development | - | - | - | - | - | 535.08 |
Operating Expenses | 351.76 | 267.47 | 212.62 | 150.3 | 186.35 | 889.4 |
Operating Income | -278.05 | -475.08 | -333.73 | -410.19 | -30.19 | -172.08 |
Interest Expense | -90.72 | -90.45 | -81.46 | -8.12 | -9.35 | -9.51 |
Interest & Investment Income | 101.95 | 107.02 | 89.04 | 25.33 | 10.04 | 30.56 |
Other Non Operating Income (Expenses) | 1.24 | 1.34 | 0.87 | -7.27 | -1.13 | -0.06 |
EBT Excluding Unusual Items | -265.58 | -457.17 | -325.28 | -400.26 | -30.62 | -151.09 |
Gain (Loss) on Sale of Investments | 6.86 | -2.89 | -1.91 | -7.33 | 10.1 | 16.54 |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -0.16 | 149.6 | - | - |
Other Unusual Items | - | - | -6.61 | - | -8.63 | - |
Pretax Income | -258.72 | -460.07 | -333.97 | -257.99 | -29.15 | -134.55 |
Income Tax Expense | -2.38 | -6.17 | 32.32 | 11.74 | -0.55 | 345.19 |
Earnings From Continuing Operations | -256.34 | -453.9 | -366.29 | -269.72 | -28.6 | -479.74 |
Minority Interest in Earnings | - | - | - | - | - | 35.48 |
Net Income | -256.34 | -453.9 | -366.29 | -269.72 | -28.6 | -444.26 |
Net Income to Common | -256.34 | -453.9 | -366.29 | -269.72 | -28.6 | -444.26 |
Shares Outstanding (Basic) | 159 | 150 | 143 | 142 | 141 | 140 |
Shares Outstanding (Diluted) | 159 | 150 | 143 | 142 | 141 | 140 |
Shares Change (YoY) | 8.89% | 4.42% | 0.95% | 0.59% | 1.01% | -8.85% |
EPS (Basic) | -1.61 | -3.04 | -2.56 | -1.90 | -0.20 | -3.18 |
EPS (Diluted) | -1.61 | -3.04 | -2.56 | -1.90 | -0.20 | -3.18 |
Free Cash Flow | -302.66 | -546.23 | -331.32 | -290.09 | 18.84 | 0.77 |
Free Cash Flow Per Share | -1.91 | -3.65 | -2.31 | -2.04 | 0.13 | 0.01 |
Gross Margin | 7.62% | -29.44% | -15.38% | -44.25% | 19.27% | 98.36% |
Operating Margin | -28.75% | -67.37% | -42.37% | -69.84% | -3.72% | -23.60% |
Profit Margin | -26.51% | -64.37% | -46.50% | -45.92% | -3.53% | -60.92% |
Free Cash Flow Margin | -31.30% | -77.46% | -42.06% | -49.39% | 2.33% | 0.11% |
EBITDA | -266.8 | -463.13 | -320.88 | -393.45 | -12.35 | -156.65 |
EBITDA Margin | -27.59% | -65.68% | -40.74% | -66.98% | -1.52% | -21.48% |
D&A For EBITDA | 11.25 | 11.95 | 12.85 | 16.74 | 17.84 | 15.43 |
EBIT | -278.05 | -475.08 | -333.73 | -410.19 | -30.19 | -172.08 |
EBIT Margin | -28.75% | -67.37% | -42.37% | -69.84% | -3.72% | -23.60% |
Revenue as Reported | 966.96 | 705.14 | 787.65 | 587.37 | 810.46 | 729.26 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.